Characterization of human immunodeficiency virus type 1 CRF01_AE env genes derived from recently infected Thai individuals |
| |
| Institution: | 1. Graduate Program in Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand;2. Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand;3. Thailand-Japan Research Collaboration Center on Emerging and Re-emerging Infections (RCC-ERI), Nonthaburi, Thailand;4. Research Institute for Microbial Diseases, Osaka University, Osaka, Japan;5. Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand;6. Department of International Health, Kobe University Graduate School of Health Sciences, 7-10-2 Tomogaoka, Suma-ku, Kobe, Hyogo 654-0142, Japan;1. Life Sciences Division, Lawrence Berkeley National Laboratory, University of California, Berkeley, CA 94720, USA;2. Engineering Division, Lawrence Berkeley National Laboratory, University of California, Berkeley, CA 94720, USA;3. The Molecular Foundry, Materials Science Division, Lawrence Berkeley National Laboratory, University of California, Berkeley, CA 94720, USA;4. National Center for Electron Microscopy, Materials Science Division, Lawrence Berkeley National Laboratory, University of California, Berkeley, CA 94720, USA;5. Max-Planck-Institute for Biochemistry, Martinsried 82152, Germany;6. FEI Company, 5600 KA Eindhoven, The Netherlands;1. Laboratory of Molecular and Cellular Biochemistry, Faculty of Dental Science, Kyushu University, Fukuoka 812-8582, Japan;2. Department of Applied Pharmacology, Kyushu Dental University, Kyushu University, Fukuoka 812-8582, Japan;3. Department of Cellular and Molecular Pharmacology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima City, Japan;1. Division of Advanced Surgical Science and Technology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan;2. Division of Advanced Cell Transplantation, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan;1. Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center/University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands;2. Center for Experimental and Molecular Medicine, Academic Medical Center/University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands;3. Division of Infectious Diseases, Academic Medical Center/University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands;4. Department of Pathology, Academic Medical Center/University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands;1. Department of Pathology and Laboratory Medicine, Medical Sciences I, Room D440, University of California, Irvine, Irvine, CA 92697-4800, USA;2. ImmPORT Therapeutics, Inc./Antigen Discovery Inc., 1 Technology Dr., Suite E309, Irvine, CA 92618, USA;3. Department of Medicine, 3052 Hewitt Hall, University of California, Irvine, Irvine, CA 92697-4068, USA;1. Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo 162-8640, Japan;2. Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan;3. Department of Infectious Diseases, Hamamatsu University School of Medicine, Hamamatsu, Japan;4. Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan |
| |
| Abstract: | Transmitted/founder virus is responsible for the establishment of human immunodeficiency virus type 1 (HIV-1) infection and induces primary anti-HIV-1 immune responses; therefore, it is important to study the viral population to understand the early events of HIV-1 infection. We amplified HIV-1 env genes from sera derived from recently infected Thai individuals, and established envelope glycoproteins (Env)-recombinant viruses. Generated Env-recombinant viruses were tested for their neutralization susceptibility to neutralizing human monoclonal antibodies (NHMAbs) and entry inhibitors, as well as being subjected to genotypic analysis. Most recombinant viruses were susceptible to neutralization by NHMAbs to Env gp41, whereas approximately one-third of the recombinant viruses were susceptible to a NHMAb against the CD4 binding site of gp120. In addition, all env genes were classified into CRF01_AE genes and showed low genetic divergence. Taken together with our previous studies on CRF01_AE env genes derived from chronically infected Thai individuals, these results suggested that the immunological and genetic characteristics of CRF01_AE Env derived from recently infected Thai individuals were different from those derived from chronically infected individuals. |
| |
| Keywords: | Recent HIV-1 infection Transmitted/founder virus CRF01_AE Envelope glycoproteins Neutralization Captured BED-ELISA |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
